New pill tested as potential weapon against Tough-to-Treat cancers
NCT ID NCT05109975
Summary
This is a first-in-human study to find a safe dose and see if a new oral drug, Debio 0123, can help control advanced solid tumors. It will enroll about 66 adults whose cancer has grown despite standard treatments. The study has two parts: first to find the right dose, and then to test that dose in specific groups of patients to check safety and look for early signs that the drug shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario de A Coruna
A Coruña, 15006, Spain
-
Institut Catala de Oncologia
Girona, 17007, Spain
-
Istituto Oncologico della Svizzera italiana - Ente Ospedaliero Cantonale
Bellinzona, 6500, Switzerland
-
Kantonsspital St. Gallen, Rorschacher Strasse 95
Sankt Gallen, 9007, Switzerland
-
START Madrid. Hospital Fundación Jimenez Diaz
Madrid, 28040, Spain
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, 49546, United States
-
Universitätsspital Zürich, Dermatologische Klinik
Zurich, 8058, Switzerland
Conditions
Explore the condition pages connected to this study.